John Mascarenhas
Impact in
- Genetics top 0.1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Papers in
- Genetics 300
- Myeloproliferative Neoplasms: Diagnosis and Treatment 284
- Hemoglobinopathies and Related Disorders 23
- Chronic Lymphocytic Leukemia Research 16
- Hematology 258
- Chronic Myeloid Leukemia Treatments 147
- Acute Myeloid Leukemia Research 140
- Multiple Myeloma Research and Treatments 34
- Co-authors
- Ronald HoffmanSrđan VerstovšekDror MevorachKeith B. ElkonDouglas TremblayRuben A. MesaLeonard NaymagonMarina Kremyanskaya
- Journals
- Blood (111 papers)HemaSphere (18 papers)Leukemia Research (13 papers)Blood Advances (13 papers)Journal of Clinical Oncology (9 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
John Mascarenhas
339 papers receiving 6.4k citations
Hit Papers
Peers
Comparison fields: 5 of 123
- Genetics 3.7k
- Hematology 3.2k
- Rheumatology 1.5k
- Immunology 1.2k
- Molecular Biology 2.7k
Countries citing papers authored by John Mascarenhas
This map shows the geographic impact of John Mascarenhas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Mascarenhas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Mascarenhas more than expected).
Fields of papers citing papers by John Mascarenhas
This network shows the impact of papers produced by John Mascarenhas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Mascarenhas. The network helps show where John Mascarenhas may publish in the future.
Co-authors
The 25 scholars most cited alongside John Mascarenhas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 3 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 39 | |
| 7 | 2023 | 4 | |
| 8 | 2023 | 24 | |
| 9 | 2023 | 1 | |
| 10 | 2022 | 8 | |
| 11 | 2021 | 4 | |
| 12 | 2021 | 39 | |
| 13 | Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor | 2020 | 5 |
| 14 | 2019 | 36 | |
| 15 | 2018 | 46 | |
| 16 | 2017 | 3 | |
| 17 | 2010 | 55 | |
| 18 | 2010 | 22 | |
| 19 | 2009 | 134 | |
| 20 | 2009 | 67 |
About John Mascarenhas
John Mascarenhas is a scholar working on Genetics, Hematology, Rheumatology, Internal Medicine and Molecular Biology, having authored 358 papers that have together received 6.4k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (284 papers), Chronic Myeloid Leukemia Treatments (147 papers), Acute Myeloid Leukemia Research (140 papers), Eosinophilic Disorders and Syndromes (75 papers), Kruppel-like factors research (69 papers), Multiple Myeloma Research and Treatments (34 papers), Hemoglobinopathies and Related Disorders (23 papers) and Chronic Lymphocytic Leukemia Research (16 papers). The work is most often cited by research in Genetics (3.7k citations), Hematology (3.2k citations), Rheumatology (1.5k citations), Immunology (1.2k citations) and Molecular Biology (2.7k citations). John Mascarenhas has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Ronald Hoffman, Srđan Verstovšek, Dror Mevorach, Keith B. Elkon, Douglas Tremblay, Ruben A. Mesa, Leonard Naymagon, Marina Kremyanskaya, Thomas D. Schiano and Raajit K. Rampal. Their work appears in journals such as Blood, HemaSphere, Leukemia Research, Blood Advances and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.